<body bgcolor="#FDF0DE"> <!-- YB-1 adenovirus oncolytic multidrug resistance gene therapy cancer-therapy dependent oncolytic adenoviruses adenovirus research cancer science --> <b><H1>YB-1 oncolytic adenovirus cancer therapy</H1></b> <b><H2>Cancer Therapy, oncolytic dependent Onkolytische Viren, Krebstherapie Krebsforschung Krebsbekämpfung</H2><br></b> <br> YB-1 dependent oncolytic adenoviruses virus Krebsforschung Cancer Therapie therapy <a href="http://www.xvir.com">YB-1 oncolytic adenovirus cancer therapy</a> </body>
YB-1 dependent oncolytic adenovirus cancer therapy

[ News ]

Welcome to XVir® Therapeutics - The YB-1 Company®

XVir® Therapeutics GmbH is a biopharmaceutical company, which provides YB-1 dependent oncolytic adenoviruses for the treatment of cancer and in particular multidrug-resistant cancer.


Detailed information about the company will be up shortly right here with the XVir®-website! Sign up here if you wish to be informed when the site is launched:

your first name:

your last name:

your e-mail-address:

 

XVir® and The YB-1 Company® are registered Trademarks of XVir® Therapeutics GmbH



XVir® Therapeutics GmbH |  Nymphenburger Str. 1  | 80335 Munich |  Germany
info@xvir.com | Tel.: +49-89-99317446 | Fax: +49-89-51556413